Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Change in Accured Expenses (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Change in Accured Expenses for 7 consecutive years, with $13.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 51.43% to $13.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.4 million, a 76.72% increase, with the full-year FY2025 number at $7.4 million, up 76.72% from a year prior.
  • Change in Accured Expenses was $13.7 million for Q4 2025 at Kymera Therapeutics, up from $664000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $13.7 million in Q4 2025 to a low of -$15.4 million in Q1 2024.
  • A 5-year average of $1.6 million and a median of $3.1 million in 2022 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: surged 642.74% in 2021, then plummeted 1069.36% in 2022.
  • Kymera Therapeutics' Change in Accured Expenses stood at $3.8 million in 2021, then dropped by 25.13% to $2.8 million in 2022, then soared by 139.02% to $6.8 million in 2023, then surged by 32.81% to $9.0 million in 2024, then surged by 51.43% to $13.7 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Change in Accured Expenses are $13.7 million (Q4 2025), $664000.0 (Q3 2025), and $4.8 million (Q2 2025).